Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008
European Urology Focus · 2026-09 · 12 (4) · 820
DOI: 10.1016/j.euf.2025.06.021 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Urology Focus, 2026-09. Verfasst von Lingyu Guo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: guolingyu1994@163.com. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Urology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: guolingyu1994@163.com.
- Department of Plastic Surgery, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, China.
Zitieren
APA
Guo, L., & An, T. (2026). Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008. European Urology Focus, 12(4), 820. https://doi.org/10.1016/j.euf.2025.06.021
Vancouver
Guo L, An T. Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008. European Urology Focus. 2026;12(4):820. doi:10.1016/j.euf.2025.06.021
BibTeX
@article{Guo2026,
author = {Guo, Lingyu and An, Tian},
title = {Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {4},
pages = {820},
doi = {10.1016/j.euf.2025.06.021}
}
EUVIMED